About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is covered by 20 issued or filed patent applications. GeoVax HIV/AIDS vaccines are designed to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1. GeoVax HIV/AIDS vaccines may be effective as therapeutics (treatment of people already infected with AIDS virus). Studies evaluating these vaccines in HIV/AIDS infected individuals are in the planning stage.
GeoVax's core HIV/AIDS vaccine technologies were developed through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and the GeoVax team.
GeoVax HIV/AIDS vaccines are moving forward in human clinical trials
administered by the HIV Vaccine Trials Network (HVTN]-Division of the
National Institutes of Health, based in Seattle, Washington. Two (2) human
trials have been successfully completed and three (3) human trials
involving over 105 individuals are currently ongoing with excellent safety
and positive anti-HIV-1 immune responses in the majority of vaccine
recipients. GeoVax and the HVTN are currently preparing for very important
Phase 2 human trials which are being planned for mid 2008. The HVT
|SOURCE GeoVax Labs, Inc.|
Copyright©2008 PR Newswire.
All rights reserved